- Home
- ANSC vs ZVRA Comparison
ANSC vs ZVRA Comparison
Compare ANSC & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANSC
- ZVRA
- Stock Information
- Founded
- ANSC 2021
- ZVRA 2006
- Country
- ANSC United States
- ZVRA United States
- Employees
- ANSC N/A
- ZVRA N/A
- Industry
- ANSC
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ANSC
- ZVRA Health Care
- Exchange
- ANSC Nasdaq
- ZVRA Nasdaq
- Market Cap
- ANSC 466.6M
- ZVRA 499.9M
- IPO Year
- ANSC 2023
- ZVRA 2015
- Fundamental
- Price
- ANSC $11.10
- ZVRA $8.62
- Analyst Decision
- ANSC
- ZVRA Strong Buy
- Analyst Count
- ANSC 0
- ZVRA 7
- Target Price
- ANSC N/A
- ZVRA $21.71
- AVG Volume (30 Days)
- ANSC 229.8K
- ZVRA 1.7M
- Earning Date
- ANSC 01-01-0001
- ZVRA 11-05-2025
- Dividend Yield
- ANSC N/A
- ZVRA N/A
- EPS Growth
- ANSC N/A
- ZVRA N/A
- EPS
- ANSC 0.20
- ZVRA 0.54
- Revenue
- ANSC N/A
- ZVRA $84,388,000.00
- Revenue This Year
- ANSC N/A
- ZVRA $336.43
- Revenue Next Year
- ANSC N/A
- ZVRA $54.26
- P/E Ratio
- ANSC $54.63
- ZVRA $16.00
- Revenue Growth
- ANSC N/A
- ZVRA 244.60
- 52 Week Low
- ANSC $10.42
- ZVRA $6.19
- 52 Week High
- ANSC $11.14
- ZVRA $13.16
- Technical
- Relative Strength Index (RSI)
- ANSC 62.98
- ZVRA 38.67
- Support Level
- ANSC $11.03
- ZVRA $8.28
- Resistance Level
- ANSC $11.10
- ZVRA $9.95
- Average True Range (ATR)
- ANSC 0.03
- ZVRA 0.55
- MACD
- ANSC 0.00
- ZVRA -0.09
- Stochastic Oscillator
- ANSC 81.82
- ZVRA 28.83
About ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.